C3N-02144
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71.87679671
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ANGIOGENESIS+0.360
- TNFA_SIGNALING_VIA_NFKB+0.360
- INFLAMMATORY_RESPONSE+0.340
- IL6_JAK_STAT3_SIGNALING+0.320
- APICAL_SURFACE+0.300
- HYPOXIA+0.300
- COAGULATION+0.290
- ALLOGRAFT_REJECTION+0.270
- IL2_STAT5_SIGNALING+0.260
Top 10 suppressed
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.410
- MYC_TARGETS_V2-0.350
- MYC_TARGETS_V1-0.330
- PANCREAS_BETA_CELLS-0.310
- OXIDATIVE_PHOSPHORYLATION-0.230
- FATTY_ACID_METABOLISM-0.170
- CHOLESTEROL_HOMEOSTASIS-0.150
- DNA_REPAIR-0.150
- BILE_ACID_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR17866819 | — | — | 0.911 |
| 2 | SRR22247245 | — | cohortMD2 | 0.899 |
| 3 | 4925248f-21e2-476e-937c-02e0a748c77b | — | — | 0.876 |
| 4 | c6396737-3587-46a7-808d-963eebe41224 | — | — | 0.868 |
| 5 | ERR2278883 | — | — | 0.863 |
| 6 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.860 |
| 7 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.859 |
| 8 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.858 |
| 9 | SRR8526722 | — | cohortMD2 | 0.857 |
| 10 | SRR8518199 | — | A | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |